유기질 폐기물의 분해촉진 방안을 통한 매립지의 조기 안정화에 관한 연구

정연규,임성균,정연균 연세대학교 산업기술연구소 1991 논문집 Vol.23 No.1

In this study, the stabilization process of solid wastes was investigated related to bio-gas production, using lysimeters filled with municipal wastes contained a high percentage of organic refuse. The lysimeters were operated four types; continual through-flushing with water, leachate recirculation, leachate recirculation with pH control, and in-situ condition. Also each type was consisted of three lysimeters and operated with detention time 3 days, 6 days, 12 days, respectively. As the results, inorganic material, ??, was decreased by physical dilution and organic materials such as COD, VS were decreased by biological activity as well as dilution. The ratio of VS to TS was decreased proportionately in the course of time. Leachate recirculation was shortening the period of stabilization by accelerating bio-degradation of organic wastes. And the reactors operated leachate recirculation with pH control accelerated the rate of gas production.

폐활성슬러지의 호기성 소화 처리시 상징액특성에 관한 연구

고광백,임성균,박준흥,정연규 연세대학교 산업기술연구소 1993 논문집 Vol.25 No.2

The main aim of this treatise is to put on observation about the supernatants during aerobic digestion, especially, the effects of pH and different solid levels on the characteristics of supernatants. Laboratory batch experiments were carried out at 20℃ and pH 7.5±0.2 on the aerobic digesion of waste activated sludge at different solid levels. As the results, this research could show that NH₄-N concentration was reduced at the fixed pH 7.5, that soluble nutrients and organics were smaller than in the general case of anaerobic digesion, and that high solid level can make supernatants poor.

물 산업 육성 정책에 대한 기업 입장에서의 제언

임성균(Seong-Keun Yim) 대한토목학회 2007 대한토목학회지 Vol.55 No.4

지열냉난방시스템에서 벤토나이트 그라우트의 열전도 특성에 관한 연구

임성균(Yim Seong Keun),안형준(An Hyung Jun),백성권(Baek Sung Kwon) 대한토목학회 2003 대한토목학회 학술대회 Vol.2003 No.10

ORiginal Article : The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels in Patients without Hepatocellular Carcinoma

( Keun Hee Kang ),( Ji Hoon Kim ),( Seong Hee Kang ),( Beom Jae Lee ),( Yeon Seok Seo ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Jong Jae Park ),( Jae Seon Kim ),( Young Tae Bak ),( Kwan Soo Byun ) The Editorial Office of Gut and Liver 2015 Gut and Liver Vol.9 No.2

Background/Aims: Prothrombin induced by vitamin K deficiency or antagonist II (PIVKA-II) is a widely used diagnostic marker for hepatocellular carcinoma (HCC). We evaluated the correlation between alcoholic liver disease (ALD) and serum PIVKA-II levels in chronic liver disease (CLD) patients. Methods: We retrospectively reviewed the medical records of 2,528 CLD patients without HCC. Among these patients, 76 exhibited serum high PIVKA-II levels of >125 mAU/mL (group 1). We categorized 76 control patients matched by age, sex, and the presence of liver cirrhosis from the remaining patients who were negative for serum PIVKA-II (group 2). Results: Group 1 revealed increased antibiotic usage (23.7% vs 2.6%, p<0.001) and incidence of ALD (60.5% vs 14.5%, p<0.001) as well as elevated aspartate aminotransferase (52.5 IU/L vs 30.5 IU/L, p=0.025) and γ glutamyl transpeptidase (67.5 IU/L vs 36.5 IU/L, p=0.005) levels compared with group 2. Further, group 1 was significantly associated with a worse Child-Pugh class than group 2. In the multivariate analysis, ALD (odds ratio [OR], 7.151; p<0.001) and antibiotic usage (OR, 5.846; p<0.001) were significantly associated with positive PIVKA-II levels. Conclusions: Our study suggests that ALD and antibiotics usage may be confounding factors when interpreting high serum PIVKA-II levels in patients without HCC. Therefore, serum PIVKA-II levels in patients with ALD or in patients administered antibiotics should be interpreted with caution. (Gut Liver, 2015;9:224-230)

Polymorphisms of thymidylate synthase gene 5'- and 3'-untranslated region and risk of gastric cancer in koreans.

Yim, Dong Jin,Kim, Ok Jun,An, Hee Jung,Kang, Haeyoun,Ahn, Dae Ho,Hwang, Seong Gyu,Oh, Doyeun,Kim, Nam Keun Potamitis Press 2010 Anticancer research Vol.30 No.6

<P>BACKGROUND: Thymidylate synthase (TS) plays an important role in the conversion of dUMP to dTMP. Polymorphisms of the TS gene affect the expression of the gene, which in turn may result in differences in the outcome of cancer chemotherapy and the progression of gastric cancer. PATIENTS AND METHODS: These types of TS polymorphism were investigated in 318 gastric cancer patients and 280 controls. A variable number of tandem repeats (VNTR; 2R or 3R) in the thymidylate synthase enhancer region (TSER), a G/C single nucleotide polymorphism within the second repeat sequence of 3R (3G or 3C), and a 6 bp insertion/deletion polymorphism (6 bp or 0 bp) in the TS 3'-untranslated region (3'-UTR) were determined using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Patients were sub-grouped by the Lauren classification. RESULTS: The TSER 2R/2R genotype had a high odds ratio in gastric cancer and for the intestinal type, but was not statistically significant (adjusted odds ratio, AOR=2.31, 95% confidence interval, CI=0.94-5.65; and AOR=2.53, 95% CI=0.98-6.54, respectively). Among the combined genotypes of TSER VNTR-3'-UTR 6 bp ins/del, 2R2R-6 bp/6 bp having 4 risk alleles conferred a significantly high risk of gastric cancer, particularly of the intestinal type (AOR=8.70, 95% CI=1.09-68.93; and AOR=10.86, 95% CI=1.32-89.09, respectively). CONCLUSION: Our results indicate that the 2R/2R-6 bp/6 bp combined genotype may be related to high gastric cancer susceptibility.</P>

HCV, Alcoholic : PO-16 ; The effects of alcohol in the elevation of serum PIVKA-2 level in patients without hepatocellular carcinoma

( Keun Hee Kang ),( Jong Eun Yeon ),( Eileen L Yoon ),( Sang Jun Suh ),( Sun Jae Lee ),( Hyun Jung Lee ),( Seong Hee Kang ),( Hae Rim Kim ),( Ji Hoon Kim ),( Hyung Joon Yim ),( Kwan Soo Byun ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-

Background: PIVKA-II is widely used as a specific marker for screening hepatocellular carcinoma (HCC) in patients with chronic liver disease. However we often face with the situation that significantly elevated PIVKA-II in patients without evidence of HCC. We aimed to evaluate the effects of alcohol in the elevation of serum PIVKA-II in the absence of HCC. Methods: People who visited Korea University Guro Hospital and have checked for PIVKA-II during November, 2002 and March, 2012 were included. There were 62 subjects whose serum PIVKA-II level were elevated (>125 mAU/mL) during their follow-up in the absence of HCC (Group 1). We determined another 67 subjects as age, sex matched control group (Group 2) who had low levels of serum PIVKA-II and no evidence of HCC. Chronic alcohol abuse was arbitrarily defined as taking ethanol more than 70 g/day for 10 years or longer. The medical charts were retrospectively reviewed. Results: Male accounted for 74.2% and 74.6% in Group 1 and 2. The median age was 55.7 years. Baseline characteristics were not different between the groups except the rates of patients with liver cirrhosis (67.7% in Group 1 vs 46.3% in Group 2, p-value=0.02). Rates of people taking vitamin K antagonist were not different. Rates of subjects who had history of chronic alcohol abuse were significantly higher in Group 1 (54.8%) than in Group 2 (26.9%) (p-value = 0.002). Presence of liver cirrhosis, history of chronic alcohol abuse were significant factors which can affect the elevated serum PIVKA-II in univariate analysis. By multivariate analysis, only the history of chronic alcohol abuse was significant (OR 2.76, 95% C.I 1.27-5.97, p-value=0.01) Conclusions: The history of chronic alcohol abuse clearly affected the serum PIVKA-II level. Our study indicates that serum PIVKA-II level may not be a useful marker for HCC in patients with alcoholic liver disease.

HCV, Alcoholic : PO-16 ; The effects of alcohol in the elevation of serum PIVKA-II level in patients without hepatocellular carcinoma

( Keun Hee Kang ),( Jong Eun Yeon ),( Eileen L Yoon ),( Sang Jun Suh ),( Sun Jae Lee ),( Hyun Jung Lee ),( Seong Hee Kang ),( Hae Rim Kim ),( Ji Hoon Kim ),( Hyung Joon Yim ),( Kwan Soo Byun ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1

Background: PIVKA-II is widely used as a specific marker for screening hepatocellular carcinoma (HCC) in patients with chronic liver disease. However we often face with the situation that significantly elevated PIVKA-II in patients without evidence of HCC. We aimed to evaluate the effects of alcohol in the elevation of serum PIVKA-II in the absence of HCC. Methods: People who visited Korea University Guro Hospital and have checked for PIVKA-II during November, 2002 and March, 2012 were included. There were 62 subjects whose serum PIVKA-II level were elevated (>125 mAU/mL) during their follow-up in the absence of HCC (Group 1). We determined another 67 subjects as age, sex matched control group (Group 2) who had low levels of serum PIVKA-II and no evidence of HCC. Chronic alcohol abuse was arbitrarily defined as taking ethanol more than 70 g/day for 10 years or longer. The medical charts were retrospectively reviewed. Results: Male accounted for 74.2% and 74.6% in Group 1 and 2. The median age was 55.7 years. Baseline characteristics were not different between the groups except the rates of patients with liver cirrhosis (67.7% in Group 1 vs 46.3% in Group 2, p-value=0.02). Rates of people taking vitamin K antagonist were not different. Rates of subjects who had history of chronic alcohol abuse were significantly higher in Group 1 (54.8%) than in Group 2 (26.9%) (p-value = 0.002). Presence of liver cirrhosis, history of chronic alcohol abuse were significant factors which can affect the elevated serum PIVKA-II in univariate analysis. By multivariate analysis, only the history of chronic alcohol abuse was significant (OR 2.76, 95% C.I 1.27-5.97, p-value=0.01) Conclusions: The history of chronic alcohol abuse clearly affected the serum PIVKA-II level. Our study indicates that serum PIVKA-II level may not be a useful marker for HCC in patients with alcoholic liver disease.

HBV : Short Term Efficacy of Tenofovir in Patients with Chronic Hepatitis B either Treatment Experienced or Na?ve

( Keun Hee Kang ),( Jong Eun Yeon ),( Eileen L Yoon ),( Sang Jun Suh ),( Hyun Jung Lee ),( Seong Hee Kang ),( Hae Rim Kim ),( Ji Hoon Kim ),( Hyung Joon Yim ),( Kwan Soo Byun ) 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1

Background: Tenofovir disoproxil fumarate (TDF), a nucleotide analogue, has potent antiviral activity and high genetic barrier, and recently approved for the treatment of chronic hepatitis B (CHB) in Korea. However, there is little clinical information on efficacy of TDF in Korean population. We evaluated short term efficacy of TDF in CHB patient who are treatment experienced (proven dug resistant mutation or suboptimal responder) or treatment-naive. Methods: A total of 56 HBeAg-positive and HBeAg-negative CHB patients who had treated with longer than 12 weeks of TDF were included. 33 patients were treatment experienced (proven drug resistant mutation or suboptimal response, Gr.1) and 23 patients were naive (Gr.2). Results: The mean age was 46.09 years and male accounted for 71.4%. Baseline characteristics of each group (Gr.1 vs. Gr.2) were not significantly different except HBV DNA (log10 IU/mL) (3.80 vs. 6.55, P<0.001), serum albumin (4.2 vs. 3.9, P=0.016), serum creatinine (0.79 vs. 0.67, P=0.007). Both groups had significant reductions from baseline in HBV DNA at Week 12 (-2.14 in Gr.1 and -4.54 in Gr.2, both groups, P<0.001). Degree of HBV DNA reductions from baseline in at Week 12 (P<0.001) was significantly different between two groups. HBV DNA undetectability of treatment week 12 (17, 56.7% vs. 3, 13.0%, P=0.001) were also significantly different between the groups. Baseline HBV DNA-adjusted degree of HBV DNA reductions at Week 12 remained significant between two groups (-2.85 vs. -3.52, P=0.009). Conclusions: After short term TDF treatment, CHB patients either treatment experience or naive can achieve effective HBV DNA reduction. Although reduction amount of HBV DNA was greater in naive patients than that of experienced group, longer duration of treatment & comparison of finite goal of treatment between each group are needed earnestly.

휘발성 지방산의 주입을 통한 생물학적 영양염류 제거공정의 효율증진에 관한 연구

임성균,고광백,김수진,정연규 대한상하수도학회 1996 상하수도학회지 Vol.10 No.3

The removal efficiencies of organic substrates, nitrogen and phosphorus in the anaerobic-aerobic biological phosphorus removal process were investigated by addition of acetic acid, propionic acid and butyric acid which are normal volatile fatty acids contained in anaerobic digester supernatants. Substrate utilization coefficients for the phosphorus release and uptake were also estimated. The effect of a VFA, which showed higher phosphorus removal efficiency than the other VFAs did, was also studied in an anaerobic-aerobic-anoxic biological nutrient removal process. For the anaerobic-aerobic process added by VFA, the phosphorus removal efficiencies were up to about 68%, 55% and 61% for the reactors of acetic acid, propionic acid and butyric acid added, respectively, which indicates the efficiencies were increased by about 8-21%, comparing to that of 47% for the reactor with no VFA added. There were no significant difference in removal efficiencies for organic substrate and NH_3-N without regard to addition of VFA. However, the removal efficiency of total nitrogen was increased in the case of VFA added, since NH_3-N was less produced. For the anaerobic-aerobic-anoxic process added VFA, the removal efficiencies for NH_3-N and PO_4^3--P were increased by 5% and 13%, respectively, comparing with them in the reactors not added VFA.